Amicus Therapeutics: A Legacy of Innovation in Rare Disease Treatment
Amicus Therapeutics is an American biopharmaceutical company that has dedicated its mission to the treatment of rare and orphan diseases. Based in Princeton, New Jersey, the company specializes in addressing complex genetic conditions, specifically focusing on lysosomal storage disorders—conditions where the body lacks specific enzymes needed to break down waste products in cells.
To combat these disorders, Amicus has pioneered two primary scientific approaches: pharmacological chaperones, which help stabilize and direct enzymes to their correct location in the cell, and enzyme replacement therapy, which involves replacing the missing enzyme in the patient's body.
[ไม่มีภาพประกอบ]
Key Facts
- Founded: February 4, 2002.
- Headquarters: Princeton, New Jersey, USA.
- Specialization: Lysosomal storage disorders and orphan diseases.
- Public Listing: Traded on Nasdaq under the symbol FOLD (Russell 2000 component).
- Acquisition: Became a subsidiary of BioMarin Pharmaceutical on April 27, 2026.
- Acquisition Value: $4.8 billion.
Corporate Evolution and Financial History
Amicus began its journey with funding from prominent venture capital firms, including Canaan Partners, New Enterprise Associates, and Radius Ventures. After an initial attempt to go public in 2006 (under the symbol AMTX) was withdrawn, the company successfully launched its IPO in 2007 under the symbol FOLD.
The company's financial trajectory has been marked by the high-risk, high-reward nature of biotechnology. For instance, in 2018, the company reported revenue of $91,245,000, though it faced a net loss of $349,089,000 as it invested heavily in research and development.
| Metric | 2017 | 2018 |
|---|---|---|
| Revenue | $36,930,000 | $91,245,000 |
| Operating Income | ($441,985,000) | ($328,777,000) |
| Net Income | ($449,121,000) | ($349,089,000) |
| Total Assets | $627,024,000 | $789,951,000 |
| Total Equity | $352,850,000 | $342,912,000 |
Strategic Growth and Product Development
The development of migalastat, a lead compound for Fabry disease, serves as a case study in the challenges of drug approval. Amicus experienced a series of partnership shifts, including a terminated collaboration with Shire in 2009 and a subsequent agreement with GlaxoSmithKline (GSK) that was terminated in 2013. While the European Union approved the drug in May 2016, the U.S. FDA initially rejected the application in November 2016 due to insufficient data, only accepting a new application in February 2018.
Expansion through Acquisitions
Amicus aggressively expanded its portfolio through strategic acquisitions to diversify its therapeutic reach:
- Callidus Biopharma (2013): Acquired to obtain enzyme replacement therapy for Pompe disease.
- Scioderm (2015): Acquired for $229 million (plus potential biodollars) for a drug targeting epidermolysis bullosa; however, this program was abandoned in 2017 after Phase III trial failure.
- MiaMed (2016): Acquired to develop treatments for CDKL5 deficiency.
- Celenex (2018): Acquired for $100 million upfront to gain access to ten early-stage gene therapies.
The BioMarin Acquisition
The company's long-term strategy culminated in a major industry consolidation. In December 2025, BioMarin Pharmaceutical reached an agreement to acquire Amicus Therapeutics for $4.8 billion. The acquisition was officially completed on April 27, 2026, transitioning Amicus into a subsidiary of BioMarin.
Frequently Asked Questions
What are lysosomal storage disorders?
These are rare genetic conditions where the body lacks specific enzymes needed to break down waste materials within the cell's lysosomes, leading to a buildup of toxic substances that damage tissues and organs.
What is the difference between pharmacological chaperones and enzyme replacement therapy?
Pharmacological chaperones are small molecules that help the body's own misfolded enzymes function correctly, while enzyme replacement therapy involves administering a synthetic version of the missing enzyme directly into the patient.
Why was the migalastat approval process so difficult in the US?
The FDA initially rejected the application in 2016, citing insufficient data, despite the drug having already received approval in the European Union.
Who acquired Amicus Therapeutics and when?
Amicus Therapeutics was acquired by BioMarin Pharmaceutical. The agreement was reached in December 2025 and the transaction was completed on April 27, 2026.
What was the final purchase price of Amicus Therapeutics?
BioMarin Pharmaceutical acquired the company for $4.8 billion.